Dendreon shares soar 132.7% on strong Ph III results for prostate cancer vacc Provenge
Data from a pivotal Phase III study of Dendreon's prostate cancer vaccine Provenge (sipuleucel-T) met its primary endpoint of improving overall survival. On the day of the news, April 14, shares in the US biotechnology firm soared 132.7% to $16.99.
In the trial, which involved 512 men with metastatic androgen-independent prostate cancer, the magnitude of the survival difference observed in the intent-to-treat population achieved the pre-specified level of statistical significance.
The agent could become the first in a new class of active cellular immunotherapies specifically designed to engage the patient's own immune system against cancer. Detailed results from the trial will be presented at the American Urological Association's annual meeting on April 28.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze